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Summary.-Synthetic glycolipids prepared by esterification of various sugars and
sorbitol, and containing various numbers of saturated or unsaturated fatty acid
residues as well as bacterial lipid A and lipopolysaccharide, were tested for mito-
genicity of splenic cells of Fischer rats and Swiss mice and for the augmentation of
humoral immune response against sheep red blood cells in these species. Subse-
quently a few of the humoral immune-response-enhancing glycolipids were com-
pared with non-enhancers in their anti-tumour activity against 13762 rat mammary
carcinoma in inbred Fischer 344 rats and Ehrlich tumour in Swiss mice. They were
given systemically after tumour inoculation and intratumourally in squalene and
Tween emulsion after intradermal MAC tumour development. It was observed that
certain structural characteristics in glycolipids with respect to the type of sugar,
the type and number of fatty-acid residues were needed for their adjuvant action of
the humoral arm of the immune response. Although humoral immune-response
enhancers were somewhat superior to non-enhancers in their anti-tumour activity,
the correlation coefficient demonstrated a lack of significant concordance. It is
concluded that glycolipids selected for their ability to augment humoral immune
responses against standard antigens need not be suspect as tumour-enhancers on
the grounds that they would elicit blocking antibodies in vivo against tumour-
associated antigens.
SYNTHETIC GLYCOLIPIDS are fatty acyl
esters of simple carbohydrates, sugar
alcohols and sugar derivatives (Behling
et al., 1976; Nigam et al., 1978; Rando
et al., 1980; Williams et al., 1979). Mono-
saccharides, when esterified with a fatty
acyl chloride (Nigam et al., 1978) give
one minor and one major fatty acyl
ester. Normally, primary hydroxyl group
(C-6) is readily esterified and this is
followed by esterification of C-1, C-2 or
C-4 (Bollenback & Parish, 1971). Disac-
charides, on the other hand, give 3-4
minor and 3 major esterified derivatives.
The glycolipids are separable by thin-
layer or column chromatography on
Silica gel using organic solvents (Chen
et al., 1973). Fatty acyl esters of glucose,
sucrose and sorbitol are known to be
wetting, emulsifying and surface-active
agents. They find industrial use in lubrica-
tion, dry cleaning, food, drug and cos-
metic industries. In spite of their wide-
spread human use, scientific enquiry on
their biological activity is either limited
or is contained in privileged information.
In recent years fatty acyl esters of sucrose
have been shown to prolong the life of
tumour-bearing animals (Kato et al.,
1971) and to have a cholesterol-lowering
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effect when ingested by animals, includ-
ing man (News Item, 1978). Our interest
in synthetic glycolipids arose because of
the similarity in their structure to that
of bacterial lipid A (O and N-fatty acyl
diglucosamine), which has immunoadju-
vant and anti-tumour properties (Lude-
ritz et al., 1978). Of the several glycolipids
that we synthesized from various sugars,
one of the glycolipids, maltose tetra-
palmitate (MTP), was extensively tested
by us for its toxicity, immunoadjuvancy
and anti-tumour potential (Nigam et al.,
1978). Behling et al. (1976) synthesized
N-fatty acyl glucosamines and showed
them to have immunoadjuvancy as well
as a protective effect against radiation. We
recently reported (El Kappany et al.,
1980) that MTP was equal or superior to
BCG, C. parvum, levamisole and pyran
copolymer in its anti-tumour action when
given after tumour implantation. It also
decreased tumour recurrence when given
after surgical tumour removal (El
Kappany et al., 1980).
Because of the potential therapeutic
advantages offered by this group of non-
toxic compounds, we investigated the
role of sugar and fatty-acid residues, and
the number of fatty-acid substituents in
synthetic glycolipids on their immuno-
adjuvancy effect and their anti-tumour
activity. Since synthetic glycolipids, like
their counterpart bacterial glycolipid,
are mitogenic for B cells, we further
sought to answer the question: will the
mitogenicity of various glycolipids for
spleen lymphocytes and the degree of
potentiation of the humoral immune
response against a xenoantigen (sheep
red blood cells:SRBC) correlate with
enhancement or inhibition of tumour
growth? It should be kept in mind that
we are determining the anti-tumour acti-
vity of synthetic glycolipids of different
structures against a weakly immunogenic
rat mammary carcinoma (13762) in syn-
geneic female Fisher rats, after s.c.
tumour implantation. Experiments were
also done with selected glycolipids when
they were injected intratumourally after
emulsification in squalene-PBS and Tween
80. Our purpose in these studies was to
see if the above immunological tests on
glycolipids correlated with their anti-
tumour activity such as to be employed
as a primary screening test for newly
synthesized glycolipids of varying struc-
tures.
MATERIALS AND METHODS
Chemicals
Sugars as well as fatty acyl chlorides and
lipopolysaccharides (LPS) from E. coli (sero-
type 055B:5) were obtained from Sigma
Chemical Co., St Louis, Mo. All other chemi-
cals and biologicals were of maximum purity
available from various commercial sources.
Bacterial glycolipid mR595 was a gift from
Dr 0. Luderitz, Max-Planck Inst., Freiburg,
W. Germany.
Animals
Swiss mice (20-24 g), and 60-day-old
inbred Fischer 344 rats were obtained from
Charles River Breeding Co., St Constant,
Que.
Syntheticglycolipids
Palmitoyl esters of arabinose, galactose,
glucose, mannose, cellobiose, lactose, maltose
and sucrose were prepared as described
previously (Nigam et al., 1978). Stearoyl and
oleyl esters of maltose were prepared in a
similar manner except that palmitoyl chlor-
ide was replaced by stearoyl and oleyl chlor-
ides respectively. Major glycolipids were
separated by thin-layer chromatography of
the mixture on Silica gel G-coated plates
using CHC13:MeOH:H20 (65:25:4) as the
developing solvent. One-inch-wide end-strips
ofglass were removed by cutting with a glass
cutter and sprayed with resorcinol reagent
(Svennerholm, 1957) and heated at 150°C for
10 min to develop the coloured glycolipid
bands. After rejoining the cut strips, the
location of the glycolipids in the middle part
was marked. Glycolipids were removed from
these areas by scraping off the Silica gel. The
scrapings were eluted with CHC13:MeOH:
H20 (65:25:4) several times to obtain the
glvcolipid fraction in solution. The solutions
were evaporated in vacuo at 40°C and the
transparent glass obtained was scraped to
give a dry or slightly sticky solid. TheV. N. NIGAM ET AL.
glycolipids were crystallized in petroleum
ether-benzene (1:1), were re-run to check for
their purity and were analysed for sugar and
fatty-acid content as described previously
(Nigam et al., 1978) using appropriate
standards. Sorbitol monolaurate, sorbitol
monopalmitate, sorbitol monostearate, sorbi-
tol tristearate and sorbitol trioleate were
kindly supplied byLonza Inc., Fairlawn, N.J.
Preparation of lipid A
Lipopolysaccharide mR595 was submitted
to acid hydrolysis according to the technique
ofGalanos et al. (1971). After drying in vacuo,
lipid A was solubilized in PBS by the addition
of triethylamine (5 ,l).
Mitogenicity 8assay
The mitogenicity of synthetic glycolipids
on spleen lymphocytes from Fischer rats and
Swiss mice was determined essentially ac-
cording to a previously described procedure
(Nigam et at., 1978). After 48 h ofincubation,
lymphocytes in each well were pulsed with
1 ,uCi [3H]dT (20Ci/mmol) for 4h andthewells
were harvested on to glass-fibre filters with
an automatic harvester. Filters after drying
were counted by liquid-scintillation spectro-
metry. Results are expressed as the stimula-
tion ratio of glycolipids according to Rosen-
streich et at. (1974).
T and B-cells fractionation
This was achieved on nylon-wool column
according to the technique described by
Julius et at. (1973). LPS was used as standard
mitogen for stimulation of B cells and
concanavalin A for T cells.
PFC assay
Swiss mice were injected i.p. with 5 x 106
or 107 SRBC and soon after were given a
single i.p. injection ofglycolipid suspension in
PBS.
Spleens were removed after 4, 5 or 7 days
and spleen-cell suspensions were prepared in
RPMI 1640 medium. PFC were enumerated
according to the plaque assay ofCunningham
& Szenberg (1968). Results were expressed as
the arithmetic mean of plaques per 106 spleen
cells.
Determination of anti-tumour activity
Mammary adenocarcinoma 13762. - A
number of Fischer 344 inbred rats were each
inoculated s.c. with 5 x 103 mammary
adenocarcinoma 13762 cells. The animals
bearing this tumour in ascitic form were
originally obtained from Dr R. Bogden,
Worcester Foundation, Mass., U.S.A. The
tumour was maintained as ascites by success-
ive i.p. transplantation. The animals were
divided into groups of 10 animals each and
they received either 0-1 ml saline i.p. or a
suspension of 10 ,tg of one of the glycolipids
i.p. in 0 1 ml saline. The injections were
repeated 3 x and the animals were examined
for tumour appearance and for tumour size.
In a second group ofexperiments designed to
employ intradermal (i.d.) tumours, we first
determined the TD50 dose of MAC cells when
they were inoculated s.c. and i.d. The values
obtained were respectively 102 for s.c. site
and 104 for i.d. site.
In order to determine if glycolipids
administered into tumours would be com-
parable with BCG and lipid A against i.d.
tumours (as shown by Kreider et al. (1976)
using this tumour model) we undertook
experiments with 105 i.d. transplanted tum-
our cells. This cell number produced tumours
in 100% of the animals. The tumours were
allowed to grow to 0-2-0-3 cm in diameter.
Each animal then received a single intra-
tumoural (i.t.) injection of 10 ,ug of a glyco-
lipid emulsion. Controls received emulsion
without the glycolipid. The emulsion was
prepared according to the method ofYarkoni
& Rapp (1979a). Briefly, each glycolipid was
dissolved in squalene and then emulsified in
PBS containing 0 2% Tween 80, to give a
final concentration of9% squalene. Squalene
was used instead of mineral oil, since Hille-
man et al. (1972) showed that it elicited few
pathological effects. Yarkoni & Rapp (1979b)
have stated that squalene or squalane could
be effective substitutes for mineral oil for
adjuvant preparations in the treatment of
human cancer. After glycolipid injection, the
animals were examined for growth of the
tumours every 2-3 days and the survival
times ofthe animals were determined.
Since the effective BCG dose in the treat-
ment of 13762 mammary adenocarcinoma
(Kreider et al., 1979) was found to be 107
bacilli, 4 x 108 bacilli/ml emulsion (Lyophil-
ized BCG- from Armand Frappier Institute,
Quebec) were prepared as described for the
glycolipids and 01 ml emulsion containing
4 x 107 bacilli were then injected i.t. as a
single injection, in order to compare anti-
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tumour potential ofBCG with the glycolipids.
Lipid A was injected in similar conditions to
glycolipids at a dose of10,g/rat. The animals
were examined for tumour necrosis, granu-
loma formation at the injection site, tumour
regression and animal survival.
Ehrlich ascites carcinoma.-Antitumour ac-
tivity of3 glycolipids and lipid A was deter-
mined against the Ehrlich tumour. This
tumour has been maintained in our labora-
tory by i.p. passage in Swiss mice. Five
groups of 10-15 mice were inoculated s.c.
with 106 Ehrlich ascites cells. The control
group received PBS, whereas the 4 others
were treated 3 x weekly with an i.p. injection
of 10 jtg of glycolipid or lipid A. Tumour
rejection and mean survival time were
evaluated for each of the groups.
Statistical analysis
The significance of anti-tumour effects on
survival time was determined with the non-
parametric Mann-Whitney U test. Student's
t test was used with mitogenicity and PFC
assays. Correlation coefficient r was calcu-
lated according to the formula of Pearson.
RESULTS
Mitogenic activity ofsynthetic glycolipids
Table I shows the composition of some
of the glycolipids based on the observed
sugar:fatty-acid ratios and their mito-
genic activity for spleen lymphocytes of
Fischer 344 rats, Swiss mice or both.
These 2 species were employedwith certain
glycolipids to see if structural change
restricted mitogenic activity for lympho-
cytes ofone or both species. Since separate
dose-response experiments for several of
the glycolipids indicated a maximum
stimulation of lymphocytes at a dose
level of 5-10 ,ug glycolipid/106 spleen cells
/0.3 ml RPMI medium, the comparisons
were made at 10 ,ug glycolipid. It was
observed that, among the glycolipids
synthesized from monosaccharides, mono-
palmitates of glucose and mannose were
inactive as mitogens with Fischer rat
spleen lymphocytes. [3H]dT incorpora-
tion (in ct/min+ s.d.) for 106 cells were
as follows: control, 295 + 35; glucose
monopalmitate 70+ 12; mannose mono-
palmitate, 55 + 8.
On the other hand, palmitates of
arabinose and galactose were active in
the same system (arabinose monopalmi-
tate, 1596 + 177, galactose monopalmitate,
1976 + 156 ct/min/106 spleen cells). With
TABLE I.-Relationship ofsynthetic glycolipid structure and in vitromitogenic stimulation
ofFischer rats and Swiss mice of the splenic lymphocytes
Stimulating compound
addeda
Maltose
Palmitic acid
Maltose monopalmitate
Maltose dipalmitate
Maltose tetrapalmitate
Maltose pentapalmitate
Maltose hexapalmitate
Maltose hexastearate
Maltose hexaoleate
Sorbitol monolaurate
Sorbitol monopalmitate
Sorbitol monostearate
Sorbitol tristearate
Sorbitol trioleate
LPS (25 tig/ml)
LPS (100 jig/ml)
Lipid A (15 [Lg/ml)
Lipid A (100 lAg/ml)
Mitogenic response
in rats E/Cb
n.d.
n.d.
2-8+0-6
0-46+ 0*07
2-1+0-4
0*42+0 06
2-9+0-7
2-9+ 0-6
2-1+_03
1*3 + 0*1
2-0+0-2
1-5+0-1
1-4+0-1
1-1+0-1
5-2+0-2
3-9+0 3
8-7
1-0
pc
<0 005
<0 005
<0 005
<0- 005
<0- 005
< 0- 005
<0- 005
n.s.
<0- 005
<0-05
<0-05
n.s.
<0- 005
<0-005
<0- 005
n.s.
Mitogenic response
in mice E/C
1-0+0-1
1-1+0-2
n.d.
0-81+ 0-1
6-6+0-7
n.d.
0-91 + 0-02
3-0+0-6
1-4+0 3
n.d.
3-5+0-5
1-8+0-3
2-8+0-6
1-1+ 0-3
5-3+ 0-3
3 -4+ 0-3
12 -4
7-6
a o-0 ml of each glycolipid was added at a concentration of 100 jig/ml in RPMI
b E/C: E, geometric mean ct/min/106unstimulated spleen cells; C, geometric meanct/min/106 unstimulated
spleen cells (control).
c P values were calculated using Student's t test.
Results are the mean of 2 separate experiments, except for lipid A where only one experiment was per-
formed.
p
n.s.
n.s.
n.s.
<0 005
n.s.
<0 005
<0-05
<0 005
<0-01
<0-005
n.s.
<0-005
<0- 005
<0- 005
<0- 005V. N. NIGAM ET AL.
major glycolipids of sucrose, lactose,
cellobiose and maltose in the range
(tetra-hexa), only sucrose gave an in-
active product, whereas lactose gave
intermediate activity and cellobiose and
maltose were equally active (data not
shown). Structural work on disaccharide-
derived glycolipids is needed to explain
differences among them. On the other
hand, we concentrated our efforts at
determining the optimum number and the
type of fatty acid attached to maltose
which would give maximum mitogenic
activity.
It was observed that di- and penta-
palmitate of maltose were non-mitogenic,
whereas mono- and hexapalmitate were
more active than maltose tetrapalmitate
in Fischer rats, but that MTP was more
efficient in mice. Maltose hexaoleate was
much less stimulatory than maltose hexa-
stearate in either species.
An additional group of glycolipids
O
x
E
a
to
0.
0 I-
u
c
W.
I
2
Swiss mice
whole spleen cells
Fischer rats
employed was that of the commercial
sorbitol esters of various fatty acids. In
this case the best mitogenic stimulator
was sorbitol monopalmitate. The other
compounds were poor stimulators except
for sorbitol tristearate (Table I, line 13)
which exhibited significant mitogenic acti-
vity for mouse lymphocytes. It should
be noted that sorbitol monopalmitate
(C16:0) was more mitogenic than sorbitol
trioleate (C18: 1) in both species.
In a subsequent experiment the mito-
genic effects of LPS and lipid A were
evaluated both in Swiss mice and Fischer
rats at various concentrations. The results
in Table I show a significant mitogenicity
for both LPS and lipid A when given at
optimal doses.
When nylon-wool-separated B and T
cells from Swiss mice were evaluated for
their proliferative response under glyco-
lipid stimulation, maltose hexastearate
(MHS) as well as LPS elicited a stimula-
T cells
25 100 25 100 25 100 25 100
MITOGEN ADDED pg ml
Vie. 1.- Mitogenic response to LPS and svnthetic glycolipid of unfractionated and fractionated
spleen cells. B and T cells from Swiss mice were separated on a nylon-wool column. (3H)TdR
incorporation is expressed as ct/min + s.d./106 cells.
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tion of B cells, whereas T cells were only
slightly affected (Fig. 1). These results
support the previous data obtained with
nude mice (Nigam et al., 1978) which
indicated a B-cell mitogenic activity for
glycolipids in vitro.
Effect of various glycolipids on the PFC
response
The first part of the experiment deter-
mined the best antigenic dose of SRBC
for PFC response elicitation in Swiss mice.
Since a 5 x 106 SRBC dose alone gave a
low response (PFC= 4-0+ 2 1) 4 days
after immunization, a dose of 107 SRBC
was used in the other experiments. The
same dose was employed in the studies of
Behling et al. (1976).
Although a 4-day delayis generally used
after SRBC immunization for the PFC
assay, a kinetic analysis was performed
to determine the day of maximal response
when SRBC were given with a synthetic
glycolipid. The number of plaques was
enumerated 4, 5 and 7 days after SRBC
immunization in the case of control and
MTP - treated groups. Another experi-
ment to determine relationships of MTP
dose to PFC response was also performed.
Results are presented in Table II. Asignifi-
cant increase was observed with a IO,1g
dose of MTP at each time after SRBC
injection, and especially on Day 7.
However, since the PFC response was
very low for the control group and hence
the degree of stimulation due to glyco-
lipid was very high, a 4-day period was
chosen for subsequent PFC determina-
tions.
In the third part of the study, various
glycolipids were tested for their effect on
the PFC response. A few mitogenically
active compounds were selected and
compared with mitogenically inactive
glycolipids (see Table I). Results in
Table III show that the glycolipids
which were better stimulators of spleen-
cell mitogenicity in vitro-namely, maltose
hexapalmitate, maltose hexastearate and
sorbitol monopalmitate were also stimu-
lators of the PFC response. Among the
3 other compounds which were either
inactive (maltose dipalmitate) or poor
activators in the mitogenicity test (sorbitol
trioleate, maltose hexaoleate), 2 of them
were poor PFC activators (maltose dipal-
mitate, sorbitol trioleate) and the other
(maltose hexaoleate) was an inhibitor of
PFC response. The PFC assay results
obtained with Fischer rats were as follows:
control, 94-1 + 9-6; MTP, 135-8 + 10-2;
MHO, 70-3 + 6-5 per 106 spleen cells.
These were in agreement with those
obtained in mice (Table III).
Anti-tumour activity of selected synthetic
glycolipids
The anti-tumour activities of maltose
di-, tetra- and hexapalmitates as well as
TABLE II.-Dose responsefor stimulation of the PFC response by maltose tetrapalmitate at
various times after immunization
MTPa
entration
Number of plaques per 106 spleen cells (arithmetic mean +s.d.) at:
I
,/mouse) 4 days pb 5 days P 7 days P
0 84-0+6-2 (83.9)c 118-2+4-3 (117-9) - 4-8+1-8 (4 5)
0-1 81 9+ 10-1 (79.6) n.S. 156-5+19-1 (154-9) <0 01 388 -+ 2 -1 (39-7) < 0-005
(0 98)d (1-31) (8 08)
1 69-5+8-3 (68 4) n.s. 121-0+7-8 (120-0) n.s. 9 8+22- (9 6) <0-005
(0-82) 1-02) (2 04)
10 162 4+20 2(161-4) <0-005 164-2+14-7 (163-2) <0 005 30-8+0-5(30 7) <0 005
(1-93) (1-39) (6.42)
Swiss mice were immunized with 107 SRBC.
a Maltose tetrapalmitate (MTP) were inoculated i.p. after suspension in PBS.
bp values were calculated using Student's t test.
cThese values are geometric means.
dThese numbers represent PFC in MTP-treated mice/PFC in control mice.
conci
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TABLE III.-Effect of treatment
Treatmenta
None
Maltose tetrapalmitate
Maltose hexastearate
Maltose hexaoleate
Maltose dipalmitate
Sorbitol monopalmitate
Sorbitol trioleate
with synthetic glycolipids on splenic PFC response to
sheep red blood cells
Number of plaques/106 spleen cells
geometric mean+s.d.
74-5+ 6-2 (74.1)c
164-6±11 4 (163 -4)
170-6+16-4 (169-6)
60-2+3-5 (59-4)
904±+10-2 (87 6)
159-0+12-3 (157-3)
96-2+15 (95 9)
a 10 Fg of each glycolipid were given i.p. in a single injection.
b P values were calculated using Student's t test.
c Numbers in parentheses are geometric means.
Swiss mice were immunized with 107 SRBC and number of PFC was measured 4 days later.
When compared with mitogenic activities in mice these values significantly correlate r= 0-80.
TABLE IV.-Anti-tumour activities of various glycolipids against mammary
adenocarcinoma 13762
Day of observation after s.c. tumour inoculation
Tumour incidence: number ofanimals with tumour/total number
Average tumour size in cm2 +s.d.
Treatment
Saline
Maltose dipalmitate
Maltose tetrapalmitate
Maltose hexapalmitate
Sorbitol monopalmitate
Sorbitol trioleate
13 17
10/10
1 -7+0-2
9/10
1-2+0-2
5/10
0 8+0 1
9/10
0 8+0 1
8/10
0 7+0 1
8/10
0 8+0 1
10/10
3 3+0 4
10/10
2-4+0-3
5/10
18 8+0 2
10/10
2 0+ 0 2
10/10
1 6+0-2
10/10
1 -6+0-2
24
7/7 (3 dead)
4-1+0-4
10/10
3 9+0 3
5/10
2-4+0-3
10/10
2-8+0 3
10/10
2 9+0-3
10/10
3 0+0 3
27 Pavalues
(t test)
7/7
4 7+0 + 5
8/8 (2 dead)
4-1+0-4 <0 01
6/10
2-8+0-3 <0.001
8/9 (2 dead)
(1 regression)
2-8+0-4 <0.005
10/10
3 5+0 3 <0 005
9/9 (1 dead)
3 5+0 3 <0005
a p values wvere calculated at 27 days
Fischer rats were inoculated s.c. with 5 x 103 mammary adenocarcinoma cells.
Average tumour size from maltose-tetrapalmitate-treated group was statistically significant (P < 0.005)
when compared with maltose-dipalmitate and sorbitol -derivatives groups.
sorbitol monopalmitate and sorbitol tri-
oleate against tumour cell inoculated s.c.
are given in Table IV. In selecting these
glycolipids, our purpose was to compare
2 poor stimulators of mitogenic and
humoral immune responses (maltose di-
palmitate and sorbitol trioleate) against
the corresponding good stimulators, viz.
maltose tetra- and hexapalmitates and
sorbitol monopalmitate. In the maltose
series, it was observed that maltose
dipalmitate neither delayed the appear-
ance of the tumour nor decreased its
growth rate. On the other hand, maltose
tetra- and hexapalmitates were compar-
able in their anti-tumour activity in
terms of tumour size but the number of
animals with tumour on Day 27 was
considerably lower (60%) in the case of
maltose tetrapalmitate than maltose hexa-
palmitate. The latter gave 100% tumours
as early as Day 17. No differences were
observed either in tumour takes or in
tumour size among the sorbitol mono-
palmitate- and sorbitol trioleate-treated
groups. However, both these compounds
<0 005
<0005
<0 05
n.s.
<0 005
<0 05
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FIG. 2. Comparison of the effects of various synthetic glycolipids, lipid A and BCG on prolongation
of survival time of 13762 rat mammary adenocarcinoma. Groups of 20-30 animals were trans-
planted i.d. with 105 mammary ascitic cells (MAC). Glycolipids and lipid A were injected i.t. at
a concentration of 10 jug per rat after emulsification in PBS-squalene 9%. BCG was administered
i.t. at a dose of 4 x 107 bacilli emulsified in PBS-squalene 9%. Numbers of the graphs are greater
than the probability that prolongation of survival compared to control group was due to chance
(Mann-Whitney U test).
delayed tumour appearance in 100% of
the animals to Day 17 compared to Day
13 for the controls. Moreover, the size of
tumours was also smaller in this group
than those in the control group. Thus
against tumour cells inoculated s.c. in the
maltose series, compounds which were
good enhancers of PFC elicited better
antitumour effects than the non-enhan-
cers. This observation was not sub-
stantiated in the comparison of sorbitol
esters. It should be noted that, although
differences in the mitogenicity of sorbitol
monopalmitate vs sorbitol trioleate are
large (sorbitol mono/tri= 2-3), the PFC
response ratio between sorbitol mono-
palmitate and sorbitol trioleate was small
(1.6) and indeed sorbitol trioleate posses-
sed a slight immunoadjuvant activity
(Table III).
In another experiment we tested the
anti-tumour effect of lipid A, BCG and
4 of the synthetic glycolipids (maltose
tetrapalmitate, maltose hexastearate, mal-
tose hexaoleate and sorbitol monopalmi-
tate), when they were emulsified in PBS
containing 9% squalene and 0-2% Tween
80 and injected into small (2-3mm
diameter) i.d. mammary adenocarcino-
mas. The results are given in Fig. 2.
It was observed that, although all of the
5 immunoadjuvants were effective in
prolonging survival times of tumour-
bearing animals and in partially arresting
the growth rate ofthe tumours, differences
in survival times between maltose hexa-
oleate- and lipid A-treated animals and
the controls were not significant. The
effectiveness of sorbitol monopalmitate,
maltose tetrapalmitate and maltose hexa-
stearate was similar, whereas BCG gave
the most promising response. The dif-
ferences in survival times among them,
however, were not significant. In theseV. N. NIGAM ET AL.
TABLE V.-Anti-tumour activity of synthetic glycolipids and Lipid A against Ehrlich
ascites carcinoma in Swiss mice
In vivo treatmenta
PBS
Maltose tetrapalmitate (MTP)
Maltose hexastearate (MHS)
Maltose hexaoleate (MHO)
Lipid A (S. minne8otta R595)
Mean survival time + s.d.
(days)
37-8+ 15-3
46 -4+ 24 - 2
43-4+ 17-4
30-5+ 15-2
34-1 + 16 - 8
Tumour rejection
0/15
1/10
2/10
0/10
0/10
a Glycolipids and lipid A were administered i.p. 3 x weekly at 10 [Lg/mouse.
b The significance of the prolongation of survival was evaluated with the Mann-Whitney U test.
Animals were inoculated s.c. with 106 Ehrlich ascitic cells.
experiments tumour regression (survivors
after 100 days) were rarely observed
(10% with BCG and 5% with MTP).
When 3 of the synthetic glycolipids
(maltose tetrapalmitate, maltose hexa-
stearate and maltose hexaoleate) were
tested for their anti-tumour activity
against Ehrlich ascitic carcinoma inocula-
ted s.c., maltose tetrapalmitate and mal-
tose hexastearate elicited tumour rejection
in 10 and 20% of the animals and pro-
longed survival time of the rest, whereas
maltose hexaoleate as well as lipid A
were ineffective by both of these criteria
(Table V).
DISCUSSION
This study is, to our knowledge, the
first of its kind in which the anti-tumour
activities of synthetic glycolipids of dif-
ferent structure have been tested against
augmentation of the humoral arm of the
immune response to a standard antigen
by the same agents. In addition, we have
utilized bacterial lipid A to compare its
immunoadjuvant and anti-tumour activi-
ties with those of synthetic glycolipids. It
was not our contention to show that an
increase in humoral immune response by a
glycolipid is the reason for its anti-
tumour activity, but initially to determine
if substances that enhance humoral im-
mune response against a standard anti-
gen to various degrees reflect a similar or
inverse order of response when tested for
anti-tumour activity. We could then
infer if the mechanisms operative in the
development of anti-tumour response by
glycolipids are affected positively or
negatively by the presence of a simul-
taneous stimulation of humoral immunity
in the tumour-bearing host. We felt that,
in addition, we would be elucidating the
structural requirements for a glycolipid
to be a humoral immune response en-
hancer and an efficient anti-tumour agent.
Since synthetic glycolipids, like bac-
terial glycolipids, are mitogenic for spleen
B lymphocytes (Rosenstreich et al., 1974),
and elicitation of humoral immune res-
ponse correlates well with B-lymphocyte
mitogenicity (Skidmore et al., 1975), we
chose mitogenic activity of synthetic
glycolipids for spleen lymphocytes as
one of the measures of their ability to
augment humoral immune response in
vivo. Indeed we found that mitogenicity
data were generally in concordance with
the estimation of antibody titres (not
shown) and of splenic PFC response in
most of our comparisons.
The elicitation of mitogenic activity in
lymphocytes depended on the type of
sugar residue and the type of fatty acid
employed in conjugation. Among mono-
saccharide-derived monopalmitoyl sugars,
glucose and mannose gave no response,
whereas arabinose and galactose gave
mitogenic products. However, the major
product in the case of glucose and man-
nose was monopalmitoyl hexose, of arabi-
nose glycolipid it was dipalmitate and of
galactose a mixture of mono- and di-
palmitate.
Among disaccharides, sucrose provided
major glycolipids which were inactive,
whereas tetra- or hexapalmitates of mal-
<0*05
<0 05
n.s.
n.s.
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tose, cellobiose and lactose were active.
It was apparent that the fructose moiety
of sucrose rendered sucrose palmitates
inactive in this mitogenicity assay. When
different bands derived from the esterifica-
tion of maltose by palmitoyl chloride were
separately analysed and tested for mito-
genicity, maltose di- and pentapalmitates
(band V) were inactive, whereas tetra-
and hexa- were active. Since esterification
at C1 is less stable, the liberation of
palmitate from C1 of maltose hexapalmi-
tate and thus the presence of free alde-
hydic group in pentapalmitate could
render it inactive. Although maltose
tripalmitate was noticed in TLC chroma-
tograms, its concentration was too low
for isolation in sufficient amounts for
these studies. Maltose dipalmitate was
apparently inactive because 6,6'-hydro-
xyls were esterified leaving C1 free.
We examined only a limited number of
fatty-acid variations. The important ob-
servation was that unsaturated fatty acyl
esters of maltose and sorbitol were
considerably less active than the corres-
ponding saturated fatty acyl esters (com-
pare maltose hexastearate vs maltose
hexaoleate, and sorbital tristearate vs
sorbitol trioleate).
The in vitro mitogenic assay of glyco-
lipids of different structures in rats
correlated partially with the experiments
done in a selected group of glycolipids
for the enhancement of the PFC response
against SRBC in vivo (r=0 76). As
shown in Table III, PFC responses
determined in mice followed the same
order as mitogenicity in vitro (r= 0.80).
Thus, fatty-acid absence at C1 (maltose
dipalmitate) or the unsaturated state of
fatty acid (hexastearate vs hexaoleate)
could be the main structural characteris-
tics that rendered a synthetic glyco-
lipid a poor stimulator of the humoral
immune response. If these considerations
are correct, the mitogenic activity of
bacterial lipid A could be due to the pro-
tection of Ci groups by PO43- and
substitution by saturated fatty acids
alone in these molecules (Luderitz et al.,
1978). Indeed, both LPS and lipid A were
found to be mitogenic for spleen cells of
Fischer rats and Swiss mice.
It should also be noted that gluco-
samine-derived N-fatty acyl glucosamines
were mitogenic (Rosenstreich et al., 1974),
although unsaturated fatty-acid substitu-
tion at this position caused a decrease in
the PFC response against SRBC; this
observation is similar to ours. However,
when a soluble antigen (human y-globulin)
was used as an antigen, Behling et al.
(1976) observed that N-oleyl glucosamine
was superior to N-stearoyl glucosamine
in eliciting anti-human Ig response. In
other studies, Kinsky (1978) observed
that liposomes made from dioleyl phos-
phatidyl choline and an antigen (DNP
aminocaproyl phosphatidyl ethanolamine)
were poorer immunogens than those
containing distearoyl phosphatidyl cho-
line. The indication from these results is
that surface-bound insoluble antigens de-
pend on the presence of saturated fatty
acid for adjuvancy, whereas the circula-
tory soluble antigens could derive adju-
vancy support from unsaturated fatty-
acid-associated compounds as well.
When the glycolipids were tested for
their anti-tumour activity after s.c.
tumour inoculation, maltose tetrapalmi-
tate obtained the maximum activity with
respect to both a delay in tumour takes
and lower tumour size. Maltose hexapal-
mitate reduced tumour size but not
tumour takes, whereas maltose dipalmi-
tate was the least active for both. Maltose
hexaoleate and BCG were inactive in this
test (not shown). Sorbitol monopalmitate
and sorbitol trioleate possessed anti-
tumour activity similar to that of maltose
hexapalmitate. The inference of these
experiments was that anti-tumour activity
of a glycolipid was only poorly correlative
(r=0.67) with stimulation of humoral
immunity. Further, anti-tumour humoral
immunity, if it developed with the
glycolipid inducers, did not interlere
with the developing anti-tumour response
Thus, anti-tumour antibodies induced by
the glycolipids would be of non-tumour-792 V. N. NIGAM ET AL.
enhancing type. The results obtained
with the Ehrlich tumour substantiated
the above observations. The poor anti-
tumour activity of lipid A against this
tumour further dramatized a lack of
correlation between anti-tumour activity
and mitogenic activity of glycolipids and
lipid A (r= 0.34) with the inclusion of
lipid A and (r= 0 80) without lipid A.
The experimentation on i.d. mammary
carcinomas, based on i.t. treatment with
glycolipids, lipid A and BCG (after
emulsification with PBS containing 9%
squalene and Tween 80), showed that
maltose hexastearate, maltose tetrapalmi-
tate and sorbitol monopalmitate were
active (P<0.05), whereas maltose hexa-
oleate and lipid A were not. BCG,
apparently, was the most effective agent.
Since in this experiment the unsaturated
fatty-acid derivative (maltose hexaoleate)
was not effective when compared to
saturated fatty-acid derivatives (maltose
tetrapalmitate and maltose hexastearate),
it can be concluded that fatty acyl deriva-
tes of unsaturated fatty acid are poor
inducers of anti-tumour response against
both existing i.d. and freshly implanted
s.c. tumour cells, when these agents are
administered by the i.t. and i.p. routes
respectively. The poor anti-tumour
activity of lipid A after i.t. treatment of
i.d. tumour was surprising since lipid A
proved to be efficacious against a murine
lymphoma and a fibrosarcoma (Parr et al.,
1973). Nevertheless, it must be empha-
sized that these tumours were highly
immunogenic, whereas Kreider et al.,
(1976) have reported a weak immuno-
genicity in the case of mammary adeno-
carcinoma 13762. This difference could be
responsible for the lack of efficacy of
lipid A. Although the mechanism of anti-
tumour activity elicited on i.t. inoculation
ofsubstances on oil droplets is not known,
it has been suggested that trehalose
dimycolate (TDM) (a glycolipid) assists
in the association of tumour antigen
(presumably soluble antigen) with oil
droplets (Ribi et al., 1976) to give an
immunogenic product. If this were the
case, glycolipids with saturated fatty
acids were more effective presenters of
tumour antigen.
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